

# Journal of Agricultural and Food Chemistry

© Copyright 1977 by the American Chemical Society

Volume 25, Number 1 January/February 1977

## Bioorganotin Chemistry. Metabolism of Organotin Compounds in Microsomal Monooxygenase Systems and in Mammals

Ella C. Kimmel, Richard H. Fish, and John E. Casida\*

Microsomal monooxygenase metabolism of tributyltin acetate yields  $\alpha$ -,  $\beta$ -,  $\gamma$ -, and  $\delta$ -hydroxybutyl-dibutyltin derivatives. The major metabolites, the  $\alpha$ - and  $\beta$ -hydroxy compounds, undergo destannylation reactions under acidic conditions to form dibutyltin derivatives and 1-butanol and 1-butene, respectively. The  $\gamma$ -hydroxy compound is further oxidized to the corresponding ketone. Tetrabutyltin yields tributyltin derivatives, via the  $\beta$ - and possibly also the  $\alpha$ -hydroxybutyltributyltins. Dibutyltin diacetate undergoes monooxygenase or nonenzymatic cleavage to butyltin derivatives. Several of the metabolites formed in the monooxygenase system are also detected in the liver and/or in the feces of mice orally administered tributyltin acetate and dibutyltin diacetate. Some of the carbon-hydroxylated tributyltin metabolites retain a high level of biological activity. Other trialkyltin derivatives (ethyl, propyl, pentyl, hexyl, and cyclohexyl) appear to undergo analogous monooxygenase reactions, whereas triphenyltin acetate is more resistant to monooxygenase attack even though it undergoes destannylation in rats. Several of these relationships are also applicable to monooxygenase metabolism of organolead compounds.


Metabolism of alkyltin compounds in liver microsomal monooxygenase (MO) systems and in mammals leads to the following sequence of destannylation (carbon-tin cleavage) reactions:  $R_4Sn \rightarrow R_3SnX \rightarrow R_2SnX_2 \rightarrow RSnX_3 \rightarrow SnX_4$  ( $X = \text{anion}$ ) (Blair, 1975; Casida et al., 1971). The first step of this destannylation reaction sequence yields derivatives of increased toxicity and potency as inhibitors of mitochondrial respiration, whereas each subsequent step progressively reduces the potency and alters the type of biological activity (Luijten, 1972; Rose, 1971; Thayer, 1974). MO studies with tributyltin acetate establish that carbon hydroxylation is the major biological oxidation reaction and that destannylation occurs due to the instability of the  $\alpha$ - and  $\beta$ -hydroxyalkyltin metabolites (Fish et al., 1975, 1976a,b).

The present study examines the metabolic fate in MO systems and in mammals of tributyltin acetate, dibutyltin diacetate, and triphenyltin acetate. It also provides comparative data on tetrabutyltin and other alkyltin and organolead compounds in the MO system.

Pesticide Chemistry and Toxicology Laboratory, Department of Entomological Sciences, University of California, Berkeley, California 94720.

### MATERIALS AND METHODS

**Chemicals.** The following organotin and organolead compounds were used (Et = ethyl, Pr = *n*-propyl, Bu = *n*-butyl, Pen = *n*-pentyl, Hex = *n*-hexyl, Oct = *n*-octyl, Cy = cyclohexyl, Ph = phenyl, and OAc = acetate):  $Et_4Sn$ ,  $Bu_4Sn$ ,  $Et_3SnCl$ ,  $Pr_3SnCl$ ,  $Bu_3SnCl$ ,  $(Bu_3Sn)_2O$ ,  $Bu_3SnOAc$ ,  $Pen_3SnOAc$ ,  $Hex_3SnOAc$ ,  $Oct_3SnCl$ ,  $Ph_3SnCl$ ,  $Ph_3SnOAc$ ,  $Et_2SnCl_2$ ,  $Bu_2SnCl_2$ ,  $Ph_2SnCl_2$ ,  $BuSnCl_3$ ,  $PhSnCl_3$ ,  $Et_4Pb$ ,  $Et_3PbOAc$ ,  $Bu_3PbOAc$ ,  $Ph_3PbOAc$ , and  $Bu_2Pb(OAc)_2$  [obtained from The Institute for Organic Chemistry TNO (Utrecht, The Netherlands), M&T Chemicals Inc. (Rahway, N.J.), or G. Widmark (Institute of Analytical Chemistry, University of Stockholm, Stockholm, Sweden)] [when not of suitable purity, the compounds were purified by distillation or by thin-layer chromatography (TLC) (see below) using solvent system A for organotin compounds and solvent system F for the organoleads];  $Cy_4Sn$ ,  $Cy_3SnOH$ ,  $(Cy_2Sn)_2O$ , and  $CySnO_2H$  (provided by Dow Chemical Co., Midland, Mich.); other unlabeled  $R_2Sn(OAc)_2$ ,  $RSn(OAc)_3$ , and  $R_2Pb(OAc)_2$  derivatives (prepared as needed by photodecomposition of  $R_4Sn$ ,  $R_3SnOAc$ , and  $R_4Pb$  compounds on silica gel chromatoplates and TLC isolation);  $1-^{14}C$ -labeled preparations of  $Bu_4Sn$ ,  $Bu_3SnOAc$ , and  $Bu_2Sn(OAc)_2$  with specific activities of 12.7, 9.5, and



**Figure 1.** Metabolic pathways for butyltin derivatives in the rat liver microsomes-NADPH system and in mice indicating the abbreviations used for various metabolites. Formulas in brackets designate  $\alpha$ -hydroxy compounds that are not sufficiently stable for isolation and other possible metabolites of  $Bu_4Sn$  on analogy with the findings using  $Bu_3SnX$ . Solid arrows indicate the in vitro NADPH-dependent metabolites while broken arrows show nonenzymatic reactions that occur at physiological pH or on acidification.

6.3 mCi/mmol, respectively, and >99% radiochemical purity (Fish et al., 1976a);  $Ph_3^{113}SnOAc$  (0.6 mCi/mmol) (provided as the hydroxide by Thompson-Hayward Chemical Co., Kansas City, Kan., and purified and converted to the acetate on TLC in solvent system A); hydroxy and keto derivatives of  $Bu_4Sn$ ,  $Bu_3SnCl$ , and  $Bu_3SnBr$  as designated in Figure 1 (Fish et al., 1976a; Lahournère and Valade, 1971). The anion substituent (X) of the organometallic compounds is not stated below since, within the series examined [ $Bu_3SnCl$ ,  $(Bu_3Sn)_2O$ , and  $Bu_3SnOAc$ ], it undergoes anion exchange on chromatography in acidic solvents (Figue, 1969; Fish et al., 1976a) and probably in MO systems (Fish et al., 1976a).

**Chromatography.** Silica gel 60 TLC plates (0.25 mm layer thickness, without fluorescent indicator, Merck) of  $20 \times 20$  cm were used for resolving the metabolites of  $^{14}C$ - and  $^{113}Sn$ -labeled compounds alone or mixed with unlabeled standards (cochromatography) and of  $10 \times 10$  cm for the metabolites of unlabeled substrates. The following three solvent systems were used to separate  $R_3SnX$  and  $R_2SnX_2$  derivatives, with  $R_4Sn$  compounds at or near the front and  $RSnX_3$  and  $SnX_4$  derivatives at the origin: (A) diisopropyl ether-HOAc (49:1); (A') two developments with diisopropyl ether-HOAc (99:1); (B) hexane-HOAc (9:1). Separation of  $Bu_4Sn$  metabolites was achieved with solvent system C, diisopropyl ether-hexane (1:1). To separate  $R_2SnX_2$  and  $RSnX_3$  derivatives, with  $SnX_4$  at the origin and  $R_3SnX$  and  $R_4Sn$  at or near the front, the systems were: (D) carbon tetrachloride-acetylacetone-HOAc (20:1:1); (E) acetylacetone-acetone-HOAc-water (15:10:2:1). For organolead compounds, solvent system F,

ethyl acetate-water-HOAc (20:1:1), separated  $R_4Pb$  (at or near the front),  $R_3PbX$  and  $R_2PbX_2$  derivatives (intermediate  $R_f$ ), and  $RPbX_3$  and  $PbX_4$  derivatives (at or near the origin).

Chromogenic reagents used in detecting organotin compounds were as follows (Casida et al., 1971): HQ—0.1% (w/v) solution of 8-hydroxy-5-quinolinesulfonic acid in 90% ethanol giving golden fluorescent spots on a purple-violet background when viewed under 365-nm uv light (Pal and Ryan, 1969); PCV—saturated solution of pyrocatechol violet in 95% ethanol yielding blue-violet spots on a yellow background (Petrowitz, 1969; Williams and Price, 1960); dithizone—0.1% (w/v) in chloroform (Petrowitz, 1969; Türler and Högl, 1961). The HQ and PCV reagents detect  $R_2SnX_2$ ,  $RSnX_3$ , and  $SnX_4$  derivatives but not  $R_4Sn$  and  $R_3SnX$  derivatives. The dithizone reagent does not detect  $R_4Sn$  compounds but yields yellow spots with  $R_3SnX$  derivatives and salmon spots with  $R_2SnX_2$ ,  $RSnX_3$ , and  $SnX_4$  derivatives. Thus,  $R_3SnX$  and  $R_2SnX_2$  derivatives are differentiated by the presence or absence of a chromogenic response with the HQ and PCV reagents and by the color obtained with dithizone. Photodestannylation (Casida et al., 1971; Williams and Price, 1960) by irradiating the chromatoplates under a germicidal uv lamp was used in order to detect  $R_4Sn$  and  $R_3SnX$  derivatives. The following sequence proved most useful with the organotins: HQ spray, detecting  $R_2SnX_2$  and  $RSnX_3$  derivatives and  $SnX_4$ ; uv irradiation; HQ spray to locate new spots due to  $R_4Sn$  and  $R_3SnX$  derivatives; PCV spray for a more permanent record. Only the dithizone reagent was employed in the studies with organoleads, the response being the same as that with the corresponding organotin derivatives. The dithizone reagent is less sensitive than the HQ and PCV reagents, the detection limits being 10–100 and 1–10  $\mu g$ /spot, respectively.

$^{14}C$ - and  $^{113}Sn$ -labeled compounds were detected by radioautography and quantitated by scraping the appropriate TLC gel regions and liquid scintillation counting (lsc).

Gas-liquid chromatography (GLC) was used for analysis of cyclohexanol and cyclohexanone (Ullrich, 1969; the retention time of cyclohexanone is about one-half that of cyclohexanol) and of 1-butene (Fish et al., 1976a).

**Microsomal Monooxygenase Reactions.** The microsomal and postmicrosomal supernatant (soluble) fractions were prepared from the livers of male albino rats (150–160 g) at 20% (w/v) fresh tissue weight equivalent in sodium phosphate buffer (0.1 M, pH 7.4). Comparable preparations were also made from the livers of male rabbits (1–3 kg) and male mice (18–20 g) and from the abdomens of houseflies (*Musca domestica* L.; strains with low to moderate MO activity).

The reaction mixtures in 2 ml of phosphate buffer contained the following components added in sequence: microsomal preparation (5.1 mg of protein, 200 mg of fresh liver weight equivalent); soluble fraction (5.5 mg of protein, 80 mg of fresh liver weight equivalent); reduced nicotinamide adenine dinucleotide phosphate (NADPH) (0 or 2  $\mu mol$ ); substrate (0.003  $\mu mol$  of [ $^{14}C$ ]butyltin derivative; 0.002, 0.007, or 0.02  $\mu mol$  of  $Ph_3^{113}SnOAc$ ; 0.5  $\mu mol$  of unlabeled compound) in ethanol (50  $\mu l$ ) injected with a syringe directly into the reaction mixture. The 25-ml Erlenmeyer flasks were incubated with shaking in air at 37 °C for 1 h.

Several extraction procedures were used depending on the substrate and the analyses to be performed. With [ $^{14}C$ ]butyltin substrates, the reaction mixture was extracted

with chloroform (5 × 7 ml), the aqueous phase was treated with trichloroacetic acid (Cl<sub>3</sub>CCOOH) (25% final concentration), and the precipitate from centrifugation was washed with acetone (1 × 3 ml) and ethanol (2 × 3 ml) to yield the acetone-ethanol extract. With Ph<sub>3</sub><sup>113</sup>SnOAc, the reaction mixture was extracted with chloroform (2 × 5 ml) and the aqueous phase was then acidified to pH 1-2 with HCl (50 μl, 6 N) and reextracted with ether-acetylacetone (9:1) mixture (2 × 5 ml) and finally with ether-ethanol (2:1) mixture (2 × 5 ml). With unlabeled substrates, the extraction utilized the ether-acetylacetone (9:1) mixture (4 ml) which gave recoveries comparable to those using chloroform as above. Identical reaction mixtures were acidified prior to extraction, a procedure which afforded increased recoveries of organometallic compounds; this treatment also decomposed some acid-labile metabolites, providing a useful criterion in certain identifications.

Organometallic products were analyzed by TLC using the PCV (organotin) or dithizone (organolead) color intensity and size of the metabolite spots to estimate yields with unlabeled substrates and lsc to quantitate labeled products. Radiocarbon designated as bound or not extracted was analyzed by combustion with the Packard Tri-Carb Model 306 sample oxidizer. Determinations of 1-[<sup>14</sup>C]butene as the oxymercuration adduct [methanol, Hg(OAc)<sub>2</sub>] and 1-[<sup>14</sup>C]butanol as the phenylcarbamate were made by described procedures (Fish et al., 1976a). For analysis of cyclohexanol and cyclohexanone, the reaction mixtures were acidified with HCl as above and extracted with ethyl acetate (1 × 2 ml) which was then added to 200 mg of distilled water and concentrated at ~80 °C to 190-195 mg total weight. A 5.0-μl aliquot was used for GLC with corrections for the extraction efficiencies of cyclohexanol and cyclohexanone and for variations in the aqueous volume resulting from evaporation of the ethyl acetate-water mixture.

**In Vivo Metabolism.** [<sup>14</sup>C]Bu<sub>3</sub>SnOAc and [<sup>14</sup>C]-Bu<sub>2</sub>Sn(OAc)<sub>2</sub> were administered in methoxytriglycol (125 μl) by stomach tube to male albino mice (20 g, Swiss-Webster strain, Horton Laboratories, Oakland, Calif.) to yield a dose of 1.2 and 1.1 mg/kg, respectively. The metabolism cages, holding conditions, and procedures for collection and quantitation of the radiocarbon content of urine, feces, and <sup>14</sup>CO<sub>2</sub> were as previously described (Krishna and Casida, 1966). The urine was diluted with water and extracted with chloroform (2 × 1 vol) before and after acidification to pH 1-2 by addition of HCl. The feces were dried and pulverized for determination of total radiocarbon content (combustion) or extraction by a multistep procedure. Thus, aliquots of the feces (40-100 mg) were homogenized in chloroform (5 ml) with a Polytron homogenizer (Kinematica GmbH, Lucerne, Switzerland), and the homogenate was centrifuged and filtered to give the chloroform-soluble fraction. The precipitate and residue on the filter paper were combined and homogenized (Polytron) in methanol (5 ml) for recovery of the methanol-soluble fraction as above. Finally, the centrifugal precipitate and filter residues were moistened with a few drops of water, acidified to pH 1-2 by addition of HCl, and reextracted with methanol as above to give the acid-methanol extract and unextractable residue (analyzed by combustion). Tissue residues were analyzed by combustion on sacrifice of the animals at 138 h after treatment. In separate experiments with each labeled compound, the 1-[<sup>14</sup>C]butene expired within 24 h after treatment was trapped and analyzed as previously described (Fish et al., 1976a). Also, the liver was removed 3 h after treatment, immediately frozen on dry ice, and then homogenized in

water (10 ml) and the homogenate extracted with chloroform (5 × 35 ml), followed by a second chloroform extraction (5 × 35 ml) after acidification of the aqueous phase to pH 1-2 with HCl.


Ph<sub>3</sub><sup>113</sup>SnOAc in methoxytriglycol was administered by the intraperitoneal (ip) route (60 μl carrier) or by stomach tube (210 μl carrier) to male albino rats (170 g, Horton Laboratories) to yield a dose of 1.6 mg/kg. Urine and feces collected daily for 10 days were analyzed for total radiotin content by direct counting of an aliquot of each urine sample and of each feces sample after homogenization in water. An aliquot (2 ml) of each feces homogenate sample was treated in the following manner: extraction with chloroform (2 × 6 ml); acidification of the aqueous phase to pH 1-2 with HCl, saturation with (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and extraction with ether-acetylacetone (9:1) (2 × 6 ml); evaporation of the aqueous phase to dryness; addition of methanol (2 ml) to the residue, sonication of the suspension for 30 min, centrifugation, and recovery of the methanol-soluble products; lsc and TLC analyses of the individual chloroform, ether-acetylacetone, and methanol extracts using two-dimensional development first with solvent system A' and then with B × 2 and, on separate plates, one-dimensional development with solvent system D. As a control, Ph<sub>3</sub><sup>113</sup>SnOAc was added directly to feces from untreated rats and analyzed by the same procedure.

## RESULTS

**Properties and Optimization of Monoxygenase System.** Rat liver microsomal preparations were used with <sup>14</sup>C-labeled substrates, mouse liver microsomes with Ph<sub>3</sub><sup>113</sup>SnOAc, and rabbit liver microsomes with unlabeled substrates, unless noted otherwise. The same metabolites (TLC pattern) of unlabeled Bu<sub>3</sub>SnX and Cy<sub>3</sub>SnX are obtained using rat or rabbit microsomal systems and of [<sup>14</sup>C]Bu<sub>3</sub>SnOAc with rat microsomes and the less active preparations of mouse and housefly microsomes. With both rat and rabbit preparations, a small amount of soluble fraction (optimum 40-100 mg fresh liver weight equivalent) increases the activity of the microsome-NADPH system although the soluble fraction is not active by itself or with NADPH. There is a considerable variation in the activity of different enzyme preparations from the same species, for unknown reasons. It is necessary in all cases to fortify the microsomal preparations with NADPH to obtain detectable metabolism of the organotin and organolead substrates (Casida et al., 1971). The rat liver microsome-NADPH system acting on [<sup>14</sup>C]Bu<sub>3</sub>SnOAc is totally inhibited by carbon monoxide and to a large extent by 4(5)-α-naphthylimidazole (Fish et al., 1976a). These findings suggest that a cytochrome P450 dependent monoxygenase system is responsible for metabolism of the organometallic substrates (Fish et al., 1976a,b).

**Monoxygenase Metabolites of Labeled and Unlabeled Organotin Compounds.** [<sup>14</sup>C]Butyltin Derivatives and Rat Liver Microsome-NADPH System. Metabolites of [<sup>14</sup>C]Bu<sub>4</sub>Sn, [<sup>14</sup>C]Bu<sub>3</sub>SnOAc, and [<sup>14</sup>C]-Bu<sub>2</sub>Sn(OAc)<sub>2</sub> were analyzed in a series of chromatographic systems that resolve all of the authentic unlabeled compounds and therefore allow tentative metabolite identification by cochromatography (Figure 2) and quantitation by lsc (Table I).

[<sup>14</sup>C]Bu<sub>4</sub>Sn yields eight identified NADPH-dependent metabolites, i.e., (β-HOBu)Bu<sub>3</sub>Sn, (γ-HOBu)Bu<sub>3</sub>Sn, and all products detected with [<sup>14</sup>C]Bu<sub>3</sub>SnOAc as the substrate (see below) except (γ-C=O-Bu)Bu<sub>2</sub>SnX. No (δ-HOBu)Bu<sub>3</sub>Sn is detected as a metabolite of Bu<sub>4</sub>Sn. There are two unusual features of the results: a large loss of radiocarbon, possibly attributable to volatilization of



**Figure 2.** Metabolites of  $[^{14}\text{C}]\text{Bu}_4\text{Sn}$ ,  $[^{14}\text{C}]\text{Bu}_3\text{SnOAc}$ , and  $[^{14}\text{C}]\text{Bu}_2\text{Sn}(\text{OAc})_2$ , formed by the rat liver microsomal-NADPH system as resolved by TLC. The substrates are indicated by dark spots and the metabolites by open spots. Compounds designated in brackets indicate that they are not detected as metabolites even though their chromatographic positions are shown. The  $\beta$ -hydroxybutyltin derivatives,  $(\beta\text{-HOBu})\text{Bu}_3\text{Sn}$  and  $(\beta\text{-HOBu})\text{Bu}_2\text{SnX}$ , decompose in acidic media so they chromatograph as  $\text{Bu}_3\text{SnX}$  and  $\text{Bu}_2\text{SnX}_2$ , respectively, in the second direction of development in systems II and III. The chromatographic systems used to analyze metabolites from different substrates were as follows:  $\text{Bu}_4\text{Sn}$ , I, II, and IV;  $\text{Bu}_3\text{SnOAc}$ , III and IV;  $\text{Bu}_2\text{Sn}(\text{OAc})_2$ , IV.

$\text{Bu}_4\text{Sn}$  during incubation, extraction, workup, and TLC analysis; extensive formation of polar metabolites which chromatograph in positions appropriate for  $\text{Bu}_3\text{SnX}$  derivatives with two sites of carbon hydroxylation or for  $\text{Bu}_2\text{SnX}_2$  derivatives with one site of carbon hydroxylation.

$[^{14}\text{C}]\text{Bu}_3\text{SnOAc}$  gives six NADPH-dependent metabolites tentatively identified by TLC cochromatography with additional structural evidence as follows (Fish et al., 1976a):  $[^{14}\text{C}](\beta\text{-HOBu})\text{Bu}_2\text{SnX}$  undergoes protodestannylation to  $[^{14}\text{C}]\text{Bu}_2\text{SnX}_2$  and 1- $[^{14}\text{C}]\text{butene}$ ;  $(\gamma\text{-HOBu})\text{Bu}_2\text{SnOAc}$  recovered as a metabolite gives an appropriate chemical ionization mass spectrum; unlabeled  $(\gamma\text{-HOBu})\text{Bu}_2\text{SnX}$  is metabolized in the rat liver microsomal-NADPH system to  $(\gamma\text{-C=O-Bu})\text{Bu}_2\text{SnX}$ .

$[^{14}\text{C}]\text{Bu}_2\text{Sn}(\text{OAc})_2$  yields one NADPH-dependent metabolite (free, polar) in a small amount but the formation of  $\text{BuSnX}_3$  does not appear to be dependent on NADPH fortification.

**Unlabeled *n*-Alkyltin Derivatives and Rabbit Liver Microsomal-NADPH System.** The extent of NADPH-dependent metabolism of tri-*n*-alkyltin compounds decreases in the order  $\text{Et}_3\text{SnX}$ ,  $\text{Pr}_3\text{SnX}$ ,  $\text{Bu}_3\text{SnX} > \text{Pen}_3\text{SnX} > \text{Hex}_3\text{SnX} \gg \text{Oct}_3\text{SnX}$ . Two-dimensional TLC (A  $\times$  B) reveals the corresponding di-*n*-alkyltin derivative as a major product in each case;  $\text{Oct}_3\text{SnX}$  yields only trace amounts of  $\text{Oct}_2\text{SnX}_2$  and no other detectable products. Each of the other substrates gives a major metabolite with the following characteristics: chromatographs above the di-*n*-alkyltin derivative in solvent system A and the same as the corresponding di-*n*-alkyltin derivative in solvent

system B (Figure 3) suggesting that it undergoes protodestannylation in the more acidic solvent used in the second direction of development; detected on developed chromatograms with HQ and PCV reagents even without uv irradiation; decomposes to the corresponding dialkyltin derivative on treatment of the incubation mixture with HCl. When this metabolite of  $\text{Bu}_3\text{SnX}$  is separated in solvent system A, it gives the yellow dithizone color of a triorganotin derivative when sprayed before evaporation of the diisopropyl ether from the chromatoplate and the salmon dithizone response of a diorganotin derivative when the solvent is completely evaporated and the gel is again acidified with HOAc before spraying (reacidification is necessary for a good color reaction). GLC analysis reveals that 1-butene is released on acidification of the reaction mixture so this metabolite yields the alkene and diorganotin derivative upon protodestannylation (Fish et al., 1976a). Finally, this  $\text{Bu}_3\text{SnX}$  metabolite cochromatographs with authentic  $(\beta\text{-HOBu})\text{Bu}_2\text{SnX}$  which also undergoes the same protodestannylation reaction. By analogy, a major metabolite of  $\text{Et}_3\text{SnX}$ ,  $\text{Pr}_3\text{SnX}$ ,  $\text{Pen}_3\text{SnX}$ , and  $\text{Hex}_3\text{SnX}$  is designated as the corresponding  $\beta$ -hydroxy compound even though authentic standards were not synthesized for direct comparisons.

The metabolites discussed above account for all of the organotin products detected with  $\text{Et}_3\text{SnX}$  and  $\text{Pr}_3\text{SnX}$  but the higher trialkyltin derivatives show additional metabolites (Figure 3). The number of metabolites depends on both the alkyl substituent and the degree of metabolism, two interrelated features.  $\text{Bu}_3\text{SnX}$  yields three

Table I. Metabolites of Tetrabutyltin, Tributyltin Acetate, and Dibutyltin Diacetate following Incubation with the Rat Liver Microsome System with and without NADPH

| Compd or fraction                             | Recovery of initial radiocarbon, % <sup>a</sup> |        |                       |        |                                      |        |
|---|---|--------|-----------------------|--------|--------------------------------------|--------|
|   | Bu <sub>4</sub> Sn                              |        | Bu <sub>3</sub> SnOAc |        | Bu <sub>2</sub> Sn(OAc) <sub>2</sub> |        |
|   | -NADPH  | +NADPH | -NADPH                | +NADPH | -NADPH                               | +NADPH |
| Tetrabutyltin Derivatives                     |   |        |                       |        |                                      |        |
| Bu <sub>4</sub> Sn                            | 95.9  | 62.9   |                       |        |                                      |        |
| (β-HOBu)Bu <sub>3</sub> Sn                    | <0.1  | 0.6    |                       |        |                                      |        |
| (γ-HOBu)Bu <sub>3</sub> Sn                    | <0.1  | 0.5    |                       |        |                                      |        |
| (δ-HOBu)Bu <sub>3</sub> Sn                    | 0.0   | 0.0    |                       |        |                                      |        |
| Tributyltin Derivatives                       |   |        |                       |        |                                      |        |
| Bu <sub>3</sub> SnX <sup>b</sup>              | 1.1   | 5.8    | 92.7                  | 70.6   |                                      |        |
| (β-HOBu)Bu <sub>2</sub> SnX                   | 0.0   | 1.6    | 0.3                   | 4.0    |                                      |        |
| (γ-HOBu)Bu <sub>2</sub> SnX                   | 0.0   | 1.4    | 0.2                   | 1.3    |                                      |        |
| (γ-C=O-Bu)Bu <sub>2</sub> SnX                 | 0.0   | 0.0    | 0.0                   | 0.2    |                                      |        |
| (δ-HOBu)Bu <sub>2</sub> SnX                   | 0.0   | 0.1    | 0.2                   | 1.4    |                                      |        |
| Di- and Monobutyltin Derivatives              |   |        |                       |        |                                      |        |
| Bu <sub>2</sub> SnX <sub>2</sub> <sup>b</sup> | 0.0   | 2.7    | 2.3                   | 8.7    | 88.9                                 | 91.3   |
| BuSnX <sub>3</sub> <sup>b</sup>               | 0.0   | 2.6    | 0.4                   | 5.5    | 3.9                                  | 2.2    |
| Unknowns                                      |   |        |                       |        |                                      |        |
| Free, apolar <sup>c</sup>                     | 0.0   | 0.5    | 0.0                   | 0.1    | 0.0                                  | 0.0    |
| Free, polar <sup>d</sup>                      | 0.0   | 18.2   | 0.8                   | 3.8    | 0.0                                  | 0.2    |
| Bound   | <0.1  | 0.5    | 0.3                   | 1.3    | 0.8                                  | 0.2    |
| Nonenzymatic products <sup>e</sup>            | 3.0   | 2.6    | 2.8                   | 3.1    | 6.4                                  | 6.1    |
| Loss correction used <sup>f</sup>             | 29.8  | 19.5   | -2.8                  | 7.3    | 12.8                                 | 8.0    |


<sup>a</sup> For compounds designated by structure the recovery values are normalized for change in specific activity on destannylation. The results are the average of two experiments with Bu<sub>4</sub>Sn, four with Bu<sub>3</sub>SnX, and two with Bu<sub>2</sub>SnX<sub>2</sub>. <sup>b</sup> Combined recovery of designated compounds in chloroform extracts and extracts of Cl<sub>3</sub>CCOOH-precipitated protein. The following percentages of the total appeared in the chloroform extracts: Bu<sub>3</sub>SnX, 67-73% from Bu<sub>3</sub>SnX substrate; Bu<sub>2</sub>SnX<sub>2</sub>, 54-75% from Bu<sub>3</sub>SnX substrate and 28-37% from Bu<sub>2</sub>SnX<sub>2</sub> substrate; BuSnX<sub>3</sub>, 70-100% from Bu<sub>3</sub>SnX and Bu<sub>2</sub>SnX<sub>2</sub> substrates. Extracts of the Cl<sub>3</sub>CCOOH-precipitated protein were not analyzed with Bu<sub>4</sub>Sn as the substrate. <sup>c</sup> One or more NADPH-dependent metabolite(s) chromatographing in the A' × B × 2 TLC solvent system between (δ-HOBu)Bu<sub>2</sub>SnX and Bu<sub>2</sub>SnX<sub>2</sub>. <sup>d</sup> NADPH-dependent metabolites chromatographing at or near the origin in the A' × B × 2 TLC solvent system and of unknown number except that only one was detected slightly above the origin with Bu<sub>2</sub>SnX<sub>2</sub> as the substrate. <sup>e</sup> Summation of all products detected with boiled microsomes + NADPH. The values for individual products are subtracted from those obtained in the fresh microsome and microsome-NADPH systems in the remaining data. <sup>f</sup> Losses on extraction, workup, and TLC analysis, some of which may be due to volatile substrates (e.g., Bu<sub>4</sub>Sn) or products (e.g., 1-butene and 1-butanol). Quantitative data on the identified products are normalized values (see footnote a) whereas the unknowns are reported directly in relation to the initial radiocarbon; some of the unknowns probably consist of carbon fragments released on formation of other organotin metabolites and this is not taken into account in the tabulation.

additional metabolites, i.e. (γ-HOBu)Bu<sub>2</sub>SnX and two diorganotin metabolites, one acid labile and the other acid stable. The pentyl compound gives the most complex pattern with two acid-stable triorganotin metabolites and comparable numbers of acid-labile tri-, acid-stable di-, and acid-labile diorganotin metabolites. The trihexyltin derivative yields two acid-stable triorganotin and one acid-stable diorganotin metabolites. Some of these acid-labile metabolites may contain β-hydroxyalkyl substituents.

Some differences are evident in studies with labeled and unlabeled butyltin compounds that may result from variations in the enzyme source and substrate level (0.003 μmol of labeled substrate with rat preparations; 0.5 μmol of unlabeled substrate with rabbit preparations) and the greater sensitivity of the radioassay. (δ-HOBu)Bu<sub>2</sub>SnX and (γ-C=O-Bu)Bu<sub>2</sub>SnX are not detected in the standard rabbit assays with unlabeled Bu<sub>3</sub>SnX. Separate studies with rat preparations established that the proportion of (δ-HOBu)Bu<sub>2</sub>SnX to other hydroxybutyl derivatives decreases as the substrate level is increased and that (γ-C=O-Bu)Bu<sub>2</sub>SnX is a detectable metabolite with this enzyme source. There is no apparent NADPH-dependent conversion of unlabeled Bu<sub>4</sub>Sn to Bu<sub>3</sub>SnX by rabbit microsomes whereas [<sup>14</sup>C]Bu<sub>4</sub>Sn yields [<sup>14</sup>C]Bu<sub>3</sub>SnX with rat microsomes. On the other hand, unlabeled Bu<sub>2</sub>SnX<sub>2</sub> undergoes NADPH-dependent conversion to BuSnX<sub>3</sub> (TLC cochromatography in D and E) but no other products are detected with rabbit microsomes, while [<sup>14</sup>C]Bu<sub>2</sub>SnX<sub>2</sub> yields only one polar NADPH-dependent metabolite and no BuSnX<sub>3</sub> with rat microsomes.

As expected, Et<sub>4</sub>Sn is extensively metabolized based on the TLC detection (A × B) of Et<sub>3</sub>SnX and Et<sub>2</sub>SnX<sub>2</sub>.

*Unlabeled Cyclohexyltin Derivatives and Rabbit Liver Microsome-NADPH System.* The TLC chromatographic pattern of the NADPH-dependent microsomal metabolites of Cy<sub>3</sub>SnX is similar to that obtained with the corresponding *n*-alkyltin derivatives (Figure 3) and the degree of metabolism falls between that of Pen<sub>3</sub>SnX and Hex<sub>3</sub>SnX. The metabolite tentatively designated as (2-HOCy)Cy<sub>2</sub>SnX is similar to (β-HOBu)Bu<sub>2</sub>SnX in relative chromatographic position and in the following additional features: undergoes protodestannylation to the dialkyltin derivative; yields a yellow dithizone color before decomposition and a salmon dithizone color after decomposition on TLC. Cy<sub>2</sub>SnX<sub>2</sub> is a major product (TLC, A × B) and CySnX<sub>3</sub> a minor one (TLC, D and E) in the microsomal NADPH-dependent metabolism of Cy<sub>3</sub>SnX. Three acid-stable triorganotin metabolites of Cy<sub>3</sub>SnX (Figure 3) each undergo photodecomposition on TLC plates to yield Cy<sub>2</sub>SnX<sub>2</sub> and additional di- or monoorganotin derivatives of greater polarity than Cy<sub>2</sub>SnX<sub>2</sub>; these metabolites are possibly hydroxylated at the 3 or 4 position of the cyclohexyl group or are formed by oxidation of these (HOCy)Cy<sub>2</sub>SnX derivatives to their corresponding ketones. The acid-stable metabolite with the highest R<sub>f</sub> in solvent system A is a monohydroxy derivative of Cy<sub>3</sub>SnX based on isolation of this metabolite and observing an appropriate chemical ionization mass spectrum (Fish et al., 1976b). An additional triorganotin metabolite is sufficiently polar for a dihydroxy derivative and its acid-labile nature suggests that one of the cyclohexyl groups is hy-



**Figure 3.** Metabolites of unlabeled trialkyltin derivatives formed by the rabbit liver microsomes-NADPH system as resolved by TLC. The substrates are indicated by dark spots. The  $\beta$ -hydroxyalkyltin compounds indicated in brackets chromatograph and undergo protodestannylation as anticipated for such products although authentic standards were not synthesized. Additional metabolites are designated as triorganotin ( $R_3SnX$ ) or diorganotin ( $R_2SnX_2$ ) based on the response to HQ before and after uv irradiation and as acid-stable (open spots) or acid-labile (spots with diagonal lines) derivatives.

droxylated at the 2 position (Fish et al., 1976b).

Examination of the organotin metabolites of other cyclohexyltin compounds revealed that  $Cy_4Sn$  is not metabolized to detectable amounts of tri- or dicyclohexyltin derivatives, possibly due in part to its low water solubility, that  $Cy_2SnX_2$  yields a small amount of  $CySnX_3$  (TLC, D and E) in a NADPH-dependent reaction and that  $CySnX_3$  does not undergo detectable metabolism.

The microsomal metabolism of cyclohexyltin compounds was compared with that of cyclohexane, cyclohexanol, and cyclohexanone using GLC analysis to determine the amount of cyclohexanol and cyclohexanone present after acidification of the reaction mixtures, extraction with ethyl acetate, and evaporation of the ethyl acetate into a small volume of water (Table II).  $Cy_4Sn$ ,  $CySnX_3$ , and cyclohexanol undergo no detectable NADPH-dependent metabolism in the rabbit liver microsomes system and, as expected (Ullrich, 1969), only cyclohexanol is evident with cyclohexane as the substrate.  $Cy_3SnX$  and  $Cy_2SnX_2$  are metabolized to similar extents, yielding almost equivalent amounts of cyclohexanol and cyclohexanone. Maximum yields of cyclohexanol and cyclohexanone are obtained from the  $Cy_3SnX$  and  $Cy_2SnX_2$  metabolites by treating the reaction mixtures with HCl and by holding the final aqueous solution after evaporation of the ethyl acetate for at least 1 day prior to analysis. These conditions pre-

**Table II.** Metabolites of Cyclohexyltin Derivatives, Cyclohexane, Cyclohexanol, and Cyclohexanone following Incubation with the Rabbit Liver Microsome System with and without NADPH Fortification

| Substrate     | NADPH | Recovery, % <sup>a</sup> |               |       |
|---------------|-------|--------------------------|---------------|-------|
|               |       | Cyclohexanol             | Cyclohexanone | Total |
| $Cy_4Sn$      | -     | <0.2                     | <0.4          |       |
|               | +     | <0.2                     | <0.4          |       |
| $Cy_3SnX$     | -     | 1.1                      | 0.5           | 1.6   |
|               | +     | 7.6                      | 8.7           | 16.3  |
| $Cy_2SnX_2$   | -     | 1.4                      | 1.1           | 2.5   |
|               | +     | 5.1                      | 6.2           | 11.3  |
| $CySnX_3$     | -     | <0.2                     | <0.4          |       |
|               | +     | <0.2                     | <0.4          |       |
| Cyclohexane   | -     | <0.2                     | <0.4          |       |
|               | +     | 1.6                      | <0.4          | 1.6   |
| Cyclohexanol  | -     | 55.0                     | <0.4          | 55.0  |
|               | +     | 55.2                     | <0.4          | 55.2  |
| Cyclohexanone | -     | 1.0                      | 24.0          | 25.0  |
|               | +     | 12.3                     | 14.2          | 26.5  |

<sup>a</sup> The results are expressed on a molar equivalent basis and are averages from eight experiments with  $Cy_3SnX$  and  $Cy_2SnX_2$ , and four experiments with the other substrates.

sumably decompose the acid-labile metabolites. It appears that one or more metabolites of  $Cy_3SnX$  and  $Cy_2SnX_2$  decompose at physiological pH or in acid solution to liberate both cyclohexanol and cyclohexanone. With each of  $Cy_3SnX$  and  $Cy_2SnX_2$ , the cyclohexanol may result from hydroxylation at the 1-carbon followed by destannylation and the cyclohexanone may be formed by hydroxylation at the 2-carbon followed by oxidation to the corresponding ketone and then destannylation. If the destannylation reaction occurred during the normal incubation at pH 7.4, the released cyclohexanol would undergo no further metabolism, but some of the cyclohexanone would be enzymatically reduced to cyclohexanol (see also Markovic et al., 1971). Further studies are in progress concerning the reactions of the hydroxycyclohexyltin derivatives.

**$Ph_3SnOAc$  and Liver Microsome-NADPH Systems.** No metabolism of unlabeled  $Ph_3SnOAc$  was detected in the rabbit microsomes-NADPH system, despite many experiments with enzyme preparations active on trialkyltin derivatives. The refractory nature of this substrate was confirmed with  $Ph_3^{113}SnOAc$  in the mouse microsomes-NADPH system, without added soluble fraction; no detectable  $Ph_2^{113}SnX_2$  was formed. As with  $[^{14}C]Bu_3SnX$ , there is extensive and NADPH-independent binding of  $Ph_3^{113}SnX$  in the microsomes system; thus, the radiotin recoveries on sequential extraction with chloroform (before acidification) and ether-acetylacetone and ether-ethanol (after acidification) are 27, 44, and 8%, respectively. At the two higher substrate levels (0.007 and 0.02  $\mu$ mol) but not at 0.002  $\mu$ mol substrate, one apolar metabolite is detected in trace amount. This metabolite is formed only on NADPH fortification, appears mostly in the chloroform extract, and chromatographs in a region (solvent system A') similar to the apolar metabolite noted later in the *in vivo* studies with rats.

**Monoxygenase Metabolites of Unlabeled Organolead Compounds.** In NADPH-dependent reactions, rabbit liver microsomes convert  $Et_4Pb$  to  $Et_3PbX$  and  $Bu_3PbX$  to  $Bu_2PbX_2$  but not  $Ph_3PbX$  to  $Ph_2PbX_2$ . These findings are based on extraction with or without addition of HCl to the incubation mixtures and TLC in solvent system F which gives  $R_f$  values as follows:  $Et_4Pb$ , not detected possibly due to volatility;  $Et_3PbX$ , 0.79;  $Bu_3PbX$ , 0.90;  $Bu_2PbX_2$ , 0.37;  $Ph_3PbX$ , 0.91;  $Ph_2PbX_2$ , 0.43. 1-

Table III. Distribution of Radiocarbon at Various Times after Oral Administration of [<sup>14</sup>C]Tributyltin Acetate and [<sup>14</sup>C]Dibutyltin Diacetate to Mice

| Compd or fraction                 | Recovery of initial radiocarbon, % |                   |                   |          | Total |
|-----------------------------------|------------------------------------|-------------------|-------------------|----------|-------|
|                                   | 0-24 h                             | 24-42 h           | 42-90 h           | 90-138 h |       |
| Tributyltin Acetate Administered  |                                    |                   |                   |          |       |
| Urine                             | 10.7                               | 3.9               | 1.5               | 0.2      | 16.3  |
| Feces                             | 25.1 <sup>a</sup>                  | 22.4 <sup>a</sup> | 4.5 <sup>a</sup>  | 0.8      | 52.8  |
| Carbon dioxide                    | 16.1                               | 3.5               | 2.4               |          | 22.0  |
| 1-Butene                          | 1.7                                |                   |                   |          | 1.7   |
| Total                             | 53.6                               | 29.8              | 8.4               | 1.0      | 92.8  |
| Dibutyltin Diacetate Administered |                                    |                   |                   |          |       |
| Urine                             | 3.0                                | 3.0               | 3.1               | 1.0      | 10.1  |
| Feces                             | No feces                           | 7.9 <sup>a</sup>  | 52.1 <sup>a</sup> | 6.0      | 66.0  |
| Carbon dioxide                    | 2.1                                | 2.0               | 3.0               |          | 7.1   |
| 1-Butene                          | 0.1                                |                   |                   |          | 0.1   |
| Total                             | 5.2                                | 12.9              | 58.2              | 7.0      | 83.3  |

<sup>a</sup> Radiocarbon recoveries in different extracts are independent of the compound administered and the time after treatment. Average values for four analyses after Bu<sub>3</sub>SnOAc treatment and three analyses after Bu<sub>2</sub>Sn(OAc)<sub>2</sub> treatment are: 29% recovery in chloroform extract, 24% in methanol extract, 28% in acidic methanol extract, 10% not extracted, and 9% loss at an unknown step.

Table IV. Products in the Liver, Feces, and Urine after Oral Administration of [<sup>14</sup>C]Tributyltin Acetate and [<sup>14</sup>C]Dibutyltin Diacetate to Mice

| Compd or fraction                | Recovery of initial radiocarbon, % <sup>a</sup> |                            |                            |                             |                             |
|----------------------------------|---|----------------------------|----------------------------|-----------------------------|-----------------------------|
|                                  | Tributyltin acetate admin.                      |                            |                            | Dibutyltin diacetate admin. |                             |
|                                  | Liver, 3 h after admin.                         | Feces, 0-42 h after admin. | Urine, 0-24 h after admin. | Liver, 3 h after admin.     | Feces, 24-90 h after admin. |
| Tributyltin Derivatives          |   |                            |                            |                             |                             |
| Bu <sub>3</sub> SnX              | 2.9 <sup>b,c</sup>                              | 14.6 <sup>b,c</sup>        | <0.1 <sup>c</sup>          |                             |                             |
| (β-HOBu)Bu <sub>2</sub> SnX      | <0.1 <sup>c</sup>                               | <0.1 <sup>c</sup>          | 0.0                        |                             |                             |
| (γ-HOBu)Bu <sub>2</sub> SnX      | 0.3 <sup>b,c</sup>                              | 0.1 <sup>c</sup>           | 0.0                        |                             |                             |
| (γ-C=O-Bu)Bu <sub>2</sub> SnX    | 0.1 <sup>b,c</sup>                              | 0.0                        | 0.0                        |                             |                             |
| (δ-HOBu)Bu <sub>2</sub> SnX      | 0.3 <sup>b,c</sup>                              | <0.1 <sup>c</sup>          | 0.0                        |                             |                             |
| Di- and Monobutyltin Derivatives |   |                            |                            |                             |                             |
| Bu <sub>2</sub> SnX <sub>2</sub> | <0.1 <sup>b</sup>                               | 6.7 <sup>b,c</sup>         | 0.2 <sup>b,c</sup>         | <0.1 <sup>b,d</sup>         | 41.1 <sup>b,e</sup>         |
| BuSnX <sub>3</sub>               | 0.0   | 3.3 <sup>b,e</sup>         | 1.0 <sup>b,c</sup>         | 0.0                         | 3.5 <sup>b,e</sup>          |
| Unknowns                         |   |                            |                            |                             |                             |
| Polar                            | 1.3 <sup>c</sup>                                | 11.4 <sup>e</sup>          | 2.5 <sup>d</sup>           | 2.6 <sup>d</sup>            | 6.4 <sup>e</sup>            |
| Not extracted plus loss          | 0.6   | 11.4                       | 7.0                        | 0.9                         | 9.0                         |
| Total                            | 5.5   | 47.5                       | 10.7                       | 3.5                         | 60.0                        |

<sup>a</sup> The results are the average of two experiments (liver analyses) or of analyses at different times after treatment (urine at 0-18 and 18-24 h, feces from Bu<sub>3</sub>SnOAc at 0-18, 18-24, and 24-42 h, and feces from Bu<sub>2</sub>Sn(OAc)<sub>2</sub> at 24-42, 42-66, and 66-90 h after administration) with no time-dependent differences in the product ratios. <sup>b</sup> Identity established by cochromatography. <sup>c</sup> Major portion recovered in initial chloroform extract. <sup>d</sup> Major portion recovered in chloroform extract of acidified fraction after initial chloroform extraction. <sup>e</sup> Major portion recovered in methanol and acidic methanol extracts.

Butene is released on acidification of the incubated Bu<sub>3</sub>PbX-microsome-NADPH system but not when NADPH is deleted. On analogy with studies on Bu<sub>3</sub>SnOAc (see above), it appears likely that the 1-butene, and at least a portion of the Bu<sub>2</sub>PbX<sub>2</sub>, originate from (β-HOBu)-Bu<sub>2</sub>PbX.

**In Vivo Metabolites of Labeled Organotin Compounds.** [<sup>14</sup>C]Bu<sub>3</sub>SnOAc and [<sup>14</sup>C]Bu<sub>2</sub>Sn(OAc)<sub>2</sub> in Mice. These butyltin derivatives undergo extensive in vivo cleavage at the tin-carbon bond and further oxidation of the liberated carbon fragment(s) to <sup>14</sup>CO<sub>2</sub>, the amount being equivalent within 90 h after oral treatment to destannylation of 66% of the [<sup>14</sup>C]Bu<sub>3</sub>SnOAc dose and 14% of the [<sup>14</sup>C]Bu<sub>2</sub>Sn(OAc)<sub>2</sub> dose (Table III). In addition, expired 1-[<sup>14</sup>C]butene is equivalent to 5.1 and 0.2% of the administered [<sup>14</sup>C]Bu<sub>3</sub>SnOAc and [<sup>14</sup>C]Bu<sub>2</sub>Sn(OAc)<sub>2</sub>, respectively. Thus, a significant portion of the in vivo metabolism of Bu<sub>3</sub>SnOAc involves (β-HOBu)Bu<sub>2</sub>SnX as an intermediate.

Three hours after oral administration of [<sup>14</sup>C]Bu<sub>3</sub>SnOAc to mice, the liver contains a large amount of Bu<sub>3</sub>SnX and detectable levels of (β-HOBu)Bu<sub>2</sub>SnX, (γ-HOBu)Bu<sub>2</sub>SnX,

(γ-C=O-Bu)Bu<sub>2</sub>SnX, (δ-HOBu)Bu<sub>2</sub>SnX, and Bu<sub>2</sub>SnX<sub>2</sub> (Table IV). Most of these products are also detected in the feces along with BuSnX<sub>3</sub>. Although insignificant levels of triorganotin derivatives appear in the urine, it contains some Bu<sub>2</sub>SnX<sub>2</sub> and BuSnX<sub>3</sub>. On administration of [<sup>14</sup>C]Bu<sub>2</sub>Sn(OAc)<sub>2</sub>, the feces contains a large amount of unmetabolized compound and some [<sup>14</sup>C]BuSnX<sub>3</sub>. Large amounts of polar and unextractable metabolites appear in the feces in each case. A portion of the urinary radiocarbon may consist of conjugates that no longer retain a tin-carbon bond. Thus, it is clear that the butyltin compounds are extensively absorbed and metabolized by pathways that, in at least their initial steps, are similar to or identical with those for the MO reactions.

The tissue residue results for [<sup>14</sup>C]Bu<sub>3</sub>SnOAc equivalents at 138 h show the highest level in brain (0.053 ppm equivalents), intermediate in bone, fat, heart, kidney, liver, lung, muscle, spleen, and testes (0.022-0.050 ppm), and the lowest in the stomach and intestine (0.012-0.015 ppm). Comparable values for [<sup>14</sup>C]Bu<sub>2</sub>Sn(OAc)<sub>2</sub> equivalents in tissues give the highest level in the brain (0.13 ppm equivalents), intermediate in heart, kidney, liver, and lung

Table V. Products in the Feces and Urine after Oral and Intraperitoneal Administration of [<sup>113</sup>Sn]Triphenyltin Acetate to Rats

| Compd or fraction <sup>a</sup>      | TLC system, R <sub>f</sub>                   |       |      | Recovery of initial radiotin, % |                   |
|-------------------------------------|--|-------|------|---------------------------------|-------------------|
|                                     | A'   | B × 2 | D    | Oral admin.                     | Ip admin.         |
|                                     | Feces, 0-72 h Oral and 0-96 h Ip             |       |      |                                 |                   |
| Ph <sub>3</sub> SnX                 | 0.83   | 0.70  | 0.84 | 28.0                            | 1.8               |
| Apolar unknown                      | 0.70   | 0.18  |      | 0.6                             | 0.4               |
| Ph <sub>2</sub> SnX <sub>2</sub>    | 0.34   | 0.28  | 0.45 | 6.4                             | 8.8               |
| PhSnX <sub>3</sub>                  | 0.00   | 0.00  | 0.14 | 21.4 <sup>b</sup>               | 14.2 <sup>b</sup> |
| SnX <sub>4</sub> and polar unknowns | 0.00   | 0.00  | 0.00 |                                 |                   |
| Bound                               |  |       |      | 21.2                            | 24.1              |
|                                     | Other Excreta and 0-240 h Total <sup>c</sup> |       |      |                                 |                   |
| Feces                               |  |       |      | 7.1                             | 13.4              |
| Urine                               |  |       |      | 1.2                             | 1.8               |
| Total                               |  |       |      | 85.9                            | 64.5              |

<sup>a</sup> Ph<sub>3</sub>SnX, the apolar unknown, and Ph<sub>2</sub>SnX<sub>2</sub> appear to the extent of 19-45, 55-71, and 0-10% in the chloroform, ether-acetylacetone, and methanol extracts, respectively. PhSnX<sub>3</sub>, SnX<sub>4</sub>, and polar unknowns appear to the extent of 9, 26, and 65% in the chloroform, ether-acetylacetone, and methanol extracts, respectively. <sup>b</sup> About half of the indicated amount is PhSnX<sub>3</sub>, while the remainder is unidentified products, probably including SnX<sub>4</sub>, remaining at the origin in solvent system D. A portion of the SnX<sub>4</sub> may result from decomposition of PhSnX<sub>3</sub> during analysis. <sup>c</sup> Based on total radiotin of 72-240 and 96-240 h feces following oral and ip administration, respectively, 0-48 h urine in each case (probably contaminated by radiotin from the feces), and of all 0-240 h excreta.

(0.058-0.082 ppm), and the lowest in the other tissues examined (0.008-0.053 ppm). These results do not differentiate [<sup>14</sup>C]butyltin derivatives retained in the tissues from metabolites formed by cleavage of the tin-carbon bond and reincorporation of the carbon fragments into tissue components.

*Ph<sub>3</sub><sup>113</sup>SnOAc in Rats.* After oral or ip administration of Ph<sub>3</sub><sup>113</sup>SnOAc to rats, most of the radiotin appears in the feces within 10 days (Table V). The excretion of radiotin is relatively slow, particularly after the ip dose where 35% of the radiotin remains in the body or is not accounted for in the excreta after the 10-day period. Although some of the administered Ph<sub>3</sub><sup>113</sup>SnX is excreted without metabolism, a significant portion is excreted as Ph<sub>2</sub>SnX<sub>2</sub>, PhSnX<sub>3</sub>, and other polar products. The minor "apolar unknown" has similar chromatographic properties to the microsomal "apolar unknown" but was not present in sufficient amount for direct cochromatography with the microsomal metabolite. The destannylation products noted in the feces are formed within the animal rather than as artifacts of analysis since: (1) less Ph<sub>3</sub>SnX appears in the feces on ip than on oral administration; (2) the proportion of Ph<sub>3</sub>SnX is highest in early feces samples whereas that of PhSnX<sub>3</sub> and other polar metabolites is highest in the later feces samples; and (3) analysis of comparable control feces directly fortified with Ph<sub>3</sub><sup>113</sup>SnOAc results in recovery (TLC) of only the original compound. A large amount of "bound" radiotin is not recovered from particulate material by the extensive extraction method used.

## DISCUSSION

Figure 1 gives a tentative metabolic pathway for butyltin compounds in the rat liver microsomal MO system. Many aspects of this pathway are also applicable to the MO systems of rabbit and mouse liver and housefly abdomens

and to the metabolism of Bu<sub>3</sub>SnX and Bu<sub>2</sub>SnX<sub>2</sub> in mice.

Bu<sub>4</sub>Sn is hydroxylated in the MO system to yield (β-HOBU)Bu<sub>3</sub>Sn and (γ-HOBU)Bu<sub>3</sub>Sn. Although not detected in these studies, trace levels of (δ-HOBU)Bu<sub>3</sub>Sn and (γ-C=O-BU)Bu<sub>3</sub>Sn might also form. On analogy with the Bu<sub>3</sub>SnOAc metabolites, Bu<sub>4</sub>Sn is also likely to yield significant amounts of (α-HOBU)Bu<sub>3</sub>Sn which undergoes a destannylation reaction in the buffer system to Bu<sub>3</sub>SnX and 1-butanol. Bu<sub>3</sub>SnX may also be formed by destannylation of (β-HOBU)Bu<sub>3</sub>Sn, with the liberation of 1-butene.

MO metabolism of Bu<sub>3</sub>SnOAc involves hydroxylation at the α-, β-, γ-, and δ-carbons, with preference for the α and β positions (Fish et al., 1975, 1976a,b). The (γ-HOBU)Bu<sub>2</sub>SnX is further oxidized to (γ-C=O-BU)Bu<sub>2</sub>SnX. Both (α-HOBU)Bu<sub>2</sub>SnX and (β-HOBU)Bu<sub>2</sub>SnX decompose to Bu<sub>2</sub>SnX<sub>2</sub> liberating 1-butanol and 1-butene, respectively, the first of these destannylation reactions occurring at physiological pH and the second on acidification. Finally, metabolism of Bu<sub>2</sub>Sn(OAc)<sub>2</sub> yields BuSnX<sub>3</sub>, perhaps both by nonenzymatic destannylation and by α- and β-carbon hydroxylation and decomposition of the hydroxy derivatives. The unidentified polar metabolites are probably formed by two or more sites of hydroxylation at different butyl groups. Bu<sub>3</sub>SnX and Bu<sub>2</sub>SnX<sub>2</sub> bind extensively in some tissue fractions, providing an inconvenience in analysis and a possible explanation for the relatively low metabolite yields.

Studies with a variety of unlabeled trialkyltin compounds and with Et<sub>4</sub>Pb, Bu<sub>3</sub>PbX, and Et<sub>4</sub>Sn suggest that portions of this general metabolic pathway are also applicable to related compounds. The major products of the biological oxidation reactions are unstable at pH 7.4 or in acidic solution, undergoing destannylation reactions to the lower alkyl-metal derivatives; the intermediates in each case are probably the α- and β-carbon hydroxylated derivatives. The number of additional metabolites depends on the number of methylene groups susceptible to attack and the overall extent of metabolism, reaching a maximum with Bu<sub>3</sub>SnX, Pen<sub>3</sub>SnX, and Cy<sub>3</sub>SnX.

Ph<sub>3</sub>SnX and Ph<sub>3</sub>PbX are quite resistant to MO metabolism. However, Ph<sub>3</sub>SnX undergoes extensive metabolism to Ph<sub>2</sub>SnX<sub>2</sub> and PhSnX<sub>3</sub> in rats by a destannylation mechanism that remains to be defined.

Three of the Bu<sub>3</sub>SnX metabolites [(γ-HOBU)Bu<sub>2</sub>SnX, (γ-C=O-BU)Bu<sub>2</sub>SnX, and (δ-HOBU)Bu<sub>2</sub>SnX] have been assayed elsewhere for potency in disturbing rat liver mitochondrial functions (effects on mitochondrial swelling and on the synthesis and hydrolysis of adenosine 5'-triphosphate). These three compounds have approximately the same potency range as Bu<sub>3</sub>SnX in all of the mitochondrial systems assayed (Aldridge and Street, 1976) and in ip toxicity to mice (Kimmel et al., 1976). Thus, some of the metabolites may contribute to the biological activity of triorganotin compounds.

## ACKNOWLEDGMENT

The early phases of this study were carried out in the Institute of Analytical Chemistry, University of Stockholm, Stockholm, Sweden. Professor Gunnar Widmark provided excellent facilities and stimulating discussions during these initial investigations. Beryl Holm of the Institute of Analytical Chemistry performed many of the GLC analyses.

## LITERATURE CITED

Aldridge, W. N., Street, B. W., Medical Research Council Laboratories, Carshalton, Surrey, England, personal communication, 1976.



- Blair, E. H., *Environ. Qual. Saf., Suppl.* 3, 406 (1975).  
 Casida, J. E., Kimmel, E. C., Holm, B., Widmark, G., *Acta Chem. Scand.* 25, 1497 (1971), and references cited therein.  
 Figge, K., *J. Chromatogr.* 39, 84 (1969).  
 Fish, R. H., Kimmel, E. C., Casida, J. E., *J. Organomet. Chem.* 93, C1 (1975).  
 Fish, R. H., Kimmel, E. C., Casida, J. E., *J. Organomet. Chem.* 118, 41 (1976a).  
 Fish, R. H., Kimmel, E. C., Casida, J. E., *Adv. Chem. Ser.*, in press (1976b).  
 Kimmel, E. C., Fish, R. H., Casida, J. E., unpublished results, 1976.  
 Krishna, J. G., Casida, J. E., *J. Agric. Food Chem.* 14, 98 (1966).  
 Lahournere, J.-C., Valade, J., *J. Organomet. Chem.* 33, C4 (1971).  
 Luijten, J. G. A., in "Organotin Compounds", Sawyer, A. K., Ed., Vol. 3, Marcel Dekker, New York, N.Y., 1972, p 931.  
 Marković, O., Theorell, H., Rao, S., *Acta Chem. Scand.* 25, 195 (1971).  
 Pal, B. K., Ryan, D. E., *Anal. Chim. Acta* 48, 227 (1969).  
 Petrowitz, H.-J., in "Thin-Layer Chromatography", Stahl, E., Ed., 2d ed, Springer-Verlag, New York, N.Y., 1969, p 664.  
 Rose, M. S., in "Pesticide Terminal Residues", Tahori, A. S., Ed., Butterworths, London, 1971, p 281.  
 Thayer, J. S., *J. Organomet. Chem.* 76, 265 (1974).  
 Türler, M., Högl, O., *Mitt. Lebensmittelunters.-Hyg.* 52, 123 (1961).  
 Ullrich, V., *Hoppe-Seyler's Z. Physiol. Chem.* 350, 357 (1969).  
 Williams, D. J., Price, J. W., *Analyst* 85, 579 (1960).


Received for review June 21, 1976. Accepted August 8, 1976. This study was supported in part by grants from the National Institutes of Health (2 P01 ES00049) and The Guggenheim Foundation.

## Permethrin Metabolism in Rats

Loretta C. Gaughan, Tadaaki Unai, and John E. Casida\*

When administered orally to male rats at 1.6 to 4.8 mg/kg, the [1*R*,*trans*], [1*RS*,*trans*], [1*R*,*cis*], and [1*RS*,*cis*] isomers of the potent pyrethroid insecticide permethrin [3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate] are rapidly metabolized, and the acid and alcohol fragments are almost completely eliminated from the body within a few days. *cis*-Permethrin is more stable than *trans*-permethrin and the *cis* compound yields four fecal ester metabolites which result from hydroxylation at the 2'-phenoxy, 4'-phenoxy, or 2-*trans*-methyl position or at both of the latter two sites. Other significant metabolites are 3-phenoxybenzoic acid (free and glucuronide and glycine conjugates), the sulfate conjugate of 4'-hydroxy-3-phenoxybenzoic acid, the sulfate conjugate of 2'-hydroxy-3-phenoxybenzoic acid (from *cis*-permethrin only), the *trans*- and *cis*-dichlorovinyl dimethylcyclopropanecarboxylic acids (free and glucuronide conjugates), and the 2-*trans*- and 2-*cis*-hydroxymethyl derivatives of each of the aforementioned *trans* and *cis* acids (free and glucuronide conjugates).

Two highly insecticidal esters of 3-phenoxybenzyl alcohol, permethrin (Elliott et al., 1973a) and phenothrin (Fujimoto et al., 1973), differ in the following respects: permethrin contains a dichlorovinyl group and phenothrin an isobutenyl group in the acid moiety; the permethrin isomers are more potent and longer acting than the corresponding phenothrin isomers (Elliott et al., 1973b, 1974; Burt et al., 1974).



The alcohol moiety of [1*R*,*trans*]- and [1*R*,*cis*]-phenothrin is rapidly metabolized and eliminated from rats treated orally with these compounds, the major excreted metabolite being 4'-hydroxy-3-phenoxybenzoic acid in free and conjugated form (Miyamoto et al., 1974; Miyamoto, 1976). Three minor fecal metabolites of [1*R*,*cis*]-phenothrin retain the ester linkage but involve oxidation at other

sites, i.e., in one metabolite the 4' position of the phenoxy group is hydroxylated, in another the *trans* methyl of the isobutenyl group is oxidized ( $R_1 = \text{CH}_3$ ;  $R_2 = \text{COOH}$ ), and in the third both of these modifications are involved plus oxidation at one of the geminal dimethyl groups (isomer unspecified) (Miyamoto, 1976). Preliminary studies with rats indicate that the metabolic fate of the acid and alcohol moieties of [1*R*,*trans*]- and [1*R*,*cis*]-permethrin is very similar to that for the corresponding moieties of phenothrin, except that in permethrin the dichlorovinyl side chain is not metabolically altered (Elliott et al., 1976).

The present study considers the residence time in the body and the metabolic fate of both the acid and alcohol moieties of [1*R*,*trans*]-, [1*RS*,*trans*]-, [1*R*,*cis*]-, and [1*RS*,*cis*]-permethrin, when these esters are administered orally to rats at dosages ranging from 1.6 to 4.8 mg/kg.

### MATERIALS AND METHODS

**Structures and Abbreviations for Chemicals.** Figure 1 gives the structures and abbreviations used for the various chemicals discussed. Permethrin is a mixture of [1*RS*,*trans*] and [1*RS*,*cis*] isomers, designated as *t*-per and *c*-per, respectively. The system used to designate the hydroxylated per isomers is illustrated for example by 4'-HO,*t*-HO,*c*-per, which represents the *c*-per derivative hydroxylated at the 4' position of the alcohol moiety and at the methyl group of the geminal dimethyl moiety which is *trans* to the carboxyl group. The hydrolysis products from the acid moieties of *t*- and *c*-per are *t*-Cl<sub>2</sub>CA and *c*-Cl<sub>2</sub>CA, respectively. The Cl<sub>2</sub>CA isomers hydroxylated at the geminal dimethyl position are: *t*-HO,*t*-Cl<sub>2</sub>CA; *c*-

\*Department of Entomological Sciences, University of California, Berkeley, California 94720.